Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

Treatment of uncontrolled asthma with dupilumab, an anti–interleukin-4 and anti–interleukin-13 receptor monoclonal antibody, in addition to usual therapy, led to a rate of severe exacerbations that was approximately 50% lower than the rate with placebo.

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 378; číslo 26; s. 2486 - 2496
Hlavní autori:	Castro, Mario, Corren, Jonathan, Pavord, Ian D, Maspero, Jorge, Wenzel, Sally, Rabe, Klaus F, Busse, William W, Ford, Linda, Sher, Lawrence, FitzGerald, J. Mark, Katelaris, Constance, Tohda, Yuji, Zhang, Bingzhi, Staudinger, Heribert, Pirozzi, Gianluca, Amin, Nikhil, Ruddy, Marcella, Akinlade, Bolanle, Khan, Asif, Chao, Jingdong, Martincova, Renata, Graham, Neil M.H, Hamilton, Jennifer D, Swanson, Brian N, Stahl, Neil, Yancopoulos, George D, Teper, Ariel
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 28.06.2018
Predmet:	Adolescent Adult Age Anti-Asthmatic Agents - adverse effects Anti-Asthmatic Agents - pharmacology Anti-Asthmatic Agents - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Asthma Asthma - classification Asthma - drug therapy Biomarkers Blood Bronchodilator Agents - therapeutic use Bronchodilators Child Clinical medicine Committees Cytokines Double-Blind Method Drug dosages Drug Therapy, Combination Eosinophilia Eosinophilia - chemically induced Female Forced Expiratory Volume - drug effects Humans Immunotherapy Inflammation Injections, Subcutaneous - adverse effects Intention to Treat Analysis Interleukin 13 Interleukin 4 Intervention Leukocytes (eosinophilic) Male Medicine Middle Aged Monoclonal antibodies Patient safety Pharmaceuticals Population Questionnaires Receptors, Interleukin-4 - antagonists & inhibitors Respiratory function Safety Young Adult Los Angeles California United States > US California
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!